PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16600694-5	2006	The results showed that (i) aspirin, fenofibrate and clofibrate decrease significantly the MCP-1 expression and secretion in human endothelial cells; (ii) the high glucose up-regulated expression of MCP-1 in endothelial cells was significantly reduced by inhibitors of NF-kB and reactive oxygen species; (iii) all drugs notably decrease the level of the reactive oxygen species and activation of NF-kB and AP-1.	Aspirin	28-35	jun proto-oncogene	Mus musculus	406-410	
9334204-0	1997	Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice.	Aspirin	75-82	jun proto-oncogene	Mus musculus	57-61	
9334204-0	1997	Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice.	Aspirin	75-82	jun proto-oncogene	Mus musculus	86-90	
9334204-7	1997	The topical pretreatment of mouse skin with aspirin markedly blocked the UVB-induced AP-1 transactivation in vivo.	Aspirin	44-51	jun proto-oncogene	Mus musculus	85-89	
9092536-0	1997	Inhibition of activator protein 1 activity and neoplastic transformation by aspirin.	Aspirin	76-83	jun proto-oncogene	Mus musculus	14-33	
9092536-5	1997	Aspirin and aspirin-like salicylates inhibited the activation of AP-1 in the same dose range as seen for the inhibition of tumor promoter-induced transformation.	Aspirin	0-7	jun proto-oncogene	Mus musculus	65-69	
9092536-5	1997	Aspirin and aspirin-like salicylates inhibited the activation of AP-1 in the same dose range as seen for the inhibition of tumor promoter-induced transformation.	Aspirin	12-19	jun proto-oncogene	Mus musculus	65-69	
9092536-8	1997	The inhibition effects on the activation of AP-1 activity by aspirin and aspirin-like salicylates may further explain the anti-carcinogenesis mechanism of action of these drugs.	Aspirin	61-68	jun proto-oncogene	Mus musculus	44-48	
9092536-8	1997	The inhibition effects on the activation of AP-1 activity by aspirin and aspirin-like salicylates may further explain the anti-carcinogenesis mechanism of action of these drugs.	Aspirin	73-80	jun proto-oncogene	Mus musculus	44-48